Great Novel Therapeutics Biotech & Medicals
Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers. The company develops drugs for cancer immunotherapy, including tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeut… Read more
Great Novel Therapeutics Biotech & Medicals (7427) - Total Assets
Latest total assets as of June 2025: NT$587.17 Million TWD
Based on the latest financial reports, Great Novel Therapeutics Biotech & Medicals (7427) holds total assets worth NT$587.17 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Great Novel Therapeutics Biotech & Medicals - Total Assets Trend (2019–2024)
This chart illustrates how Great Novel Therapeutics Biotech & Medicals’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Great Novel Therapeutics Biotech & Medicals - Asset Composition Analysis
Current Asset Composition (December 2024)
Great Novel Therapeutics Biotech & Medicals's total assets of NT$587.17 Million consist of 90.4% current assets and 9.6% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 23.4% |
| Accounts Receivable | NT$1.39 Million | 0.2% |
| Inventory | NT$3.01 Million | 0.5% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$27.53 Million | 4.2% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Great Novel Therapeutics Biotech & Medicals's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Great Novel Therapeutics Biotech & Medicals's current assets represent 90.4% of total assets in 2024, an increase from 15.8% in 2019.
- Cash Position: Cash and equivalents constituted 23.4% of total assets in 2024, down from 29.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 45.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 4.2% of total assets.
Great Novel Therapeutics Biotech & Medicals Competitors by Total Assets
Key competitors of Great Novel Therapeutics Biotech & Medicals based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Great Novel Therapeutics Biotech & Medicals - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Great Novel Therapeutics Biotech & Medicals generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Great Novel Therapeutics Biotech & Medicals is currently not profitable relative to its asset base.
Great Novel Therapeutics Biotech & Medicals - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 30.32 | 29.92 | 3.37 |
| Quick Ratio | 30.15 | 29.77 | 3.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$508.21 Million | NT$ 606.43 Million | NT$ 28.35 Million |
Great Novel Therapeutics Biotech & Medicals - Advanced Valuation Insights
This section examines the relationship between Great Novel Therapeutics Biotech & Medicals's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.58 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 2.8% |
| Total Assets | NT$662.60 Million |
| Market Capitalization | $34.39 Million USD |
Valuation Analysis
Below Book Valuation: The market values Great Novel Therapeutics Biotech & Medicals's assets below their book value (0.05 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Great Novel Therapeutics Biotech & Medicals's assets grew by 2.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Great Novel Therapeutics Biotech & Medicals (2019–2024)
The table below shows the annual total assets of Great Novel Therapeutics Biotech & Medicals from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$662.60 Million | +2.75% |
| 2023-12-31 | NT$644.85 Million | +72.95% |
| 2022-12-31 | NT$372.85 Million | +62.13% |
| 2021-12-31 | NT$229.96 Million | +82.72% |
| 2020-12-31 | NT$125.85 Million | +46.89% |
| 2019-12-31 | NT$85.67 Million | -- |